Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases.

Q1 Pharmacology, Toxicology and Pharmaceutics

Progress in medicinal chemistry Pub Date : 2009-01-01 DOI:10.1016/s0079-6468(09)04803-6

Stephen Shuttleworth, Franck Silva, Cyrille Tomassi, Alexander Cecil, Thomas Hill, Helen Rogers, Paul Townsend

引用次数: 11

查看原文本刊更多论文

用于治疗慢性疾病的磷酸肌苷3-激酶(PI3K)抑制剂的设计和开发进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in medicinal chemistry Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

15.60

自引率

0.00%

发文量

期刊介绍： This series has a long established reputation for excellent coverage of almost every facet of Medicinal Chemistry and is one of the most respected and instructive sources of information on the subject. The latest volume certifies to the continuing success of a unique series reflecting current progress in a broadly developing field of science.